Table 3A.

The mean (95% Cl) length of various FMD infection phases obtained from the best-fit Accelerated Failure Time (AFT) model.

FMD phases	Serotype			Exposure method
	O	Asia1	A	CTC	PTC	IDL	SN
THRESHOLD-DEFINED APPROACH
Incubation	3.1 (2.7–3.6)	3.1 (2.6–3.7)	4 (3.5–4.4)	5.2 (4.2–6.4)	3.6 (3.2–4.1)	1.8 (1.4–2.3)	4 (3.5–4.3)
Latent	1.6 (1.4–2)	1.4 (1.2–1.8)	1.3 (1.1–1.5)	1.7 (1.3–2.2)	1.5 (1.3–1.8)	1.3 (1–1.8)	1.3 (1.2–1.5)
Subclinical infectious	2.1 (1.6–2.6)	1.8 (1.4–2.4)	3.1 (2.5–3.8)	3.6 (2.7–5)	2.4 (2–2.8)	1.2 (0.7–2.1)	2.6 (2.2–3)
Clinical infectious	7.8 (6.6–9.1)	8.6 (6.7–11)	8.4 (7.4–9.6)	6 (4.5–8)	9 (7.7–10.5)	9.5 (7.1–12.6)	9 (8–10.2)
Total infectious	9.6 (8.3–11)	10.7 (8.5–13.4)	11.2 (10–12.6)	10 (7.7–13)	11 (9.5–12.5)	9.4 (7.3–12.1)	11.7 (10.4–13.1)
NON-THRESHOLD APPROACH
Incubation	3.2 (2.8–3.6)	3.1 (2.7–3.7)	4 (3.5–4.4)	5.2 (4.3–6.4)	3.6 (3.2–4.1)	1.8 (1.4–2.3)	4 (3.5–4.3)
Latent	1.3 (1.1–1.5)	1.2 (1–1.4)	1.3 (1.2–1.5)	1.7 (1.3–2.1)	1.3 (1.1–1.5)	1 (0.8–1.3)	1.2 (1.1–1.3)
Subclinical infectious	2.1 (1.8–2.5)	2 (1.6–2.4)	3 (2.5–3.6)	3.7 (2.8–4.8)	2.6 (2.2–3.0)	1.1 (0.8–1.7)	2.7 (2.3–3)
Clinical infectious	9.9 (8–12.4)	10.1 (7.1–14.3)	10.7 (8.7–13.3)	6.6 (4.7–9.2)	10.8 (9–13.1)	13.8 (7.8–24.6)	11.1 (9.3–13.3)
Total infectious	12.2 (10–15)	12.5 (9.2–17.1)	13.6 (11.3–16.5)	10.4 (7.7–14)	12.9 (10.9–15.2)	14.1 (8.4–23.7)	14.1 (12–16.5)

The outcomes are stratified by serotypes and exposure methods for both threshold approaches for definition of infectiousness.